US EditionTGA approves first Eylea biosimilar for use in Australia
Summary by Insight
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
TGA approves first Eylea biosimilar for use in Australia
Celltrion's Eylea biosimilar for eye disease treatment has been approved for the Australian market.Image: CelltrionKorea-based global pharmaceutical company Celltrion has announced approval from the Therapeutic Goods Administration (TGA) of Australia of its ophthalmic treatment ‘Eydenzelt’ (ingredient name: Aflibercept). ‘Eydenzelt’ is a biosimilar of Regeneron’s Eylea and is approved for the treatment of myopic choroidal neovascularisation. As …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
